Dr. Vishala Chindalore, MD
Claim this profilePinnacle Research Group, LLC
Studies Subtalar Arthritis
Studies Systemic Lupus Erythematosus
10 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Vishala Chindalore, MD is currently running
Ianalumab
for Lupus
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Recruiting1 award Phase 31 criteria
Ianalumab
for Lupus
This trial will test if ianalumab, an injection given regularly, is safe and effective for people with active systemic lupus erythematosus (SLE). The medication aims to calm down their overactive immune system to reduce inflammation and damage.
Recruiting1 award Phase 3
More about Vishala Chindalore, MD
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Vishala Chindalore, MD has experience with
- Tildrakizumab
- Ianalumab
- Galvani System
- Baricitinib
- VIB1116
- Matching Placebo Injections
Breakdown of trials Vishala Chindalore, MD has run
Subtalar Arthritis
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Lupus
Psoriatic Arthritis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Vishala Chindalore, MD specialize in?
Is Vishala Chindalore, MD currently recruiting for clinical trials?
Are there any treatments that Vishala Chindalore, MD has studied deeply?
What is the best way to schedule an appointment with Vishala Chindalore, MD?
What is the office address of Vishala Chindalore, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.